Clinical Trial Update: Neoadjuvant Therapy of Targeted Immunotherapy Combined With Chemotherapy for Locally Advanced HNSCC [Phase 2]

View source ↗

Summary

Phase 2 neoadjuvant trial evaluating targeted PD-L1 immunotherapy combined with chemotherapy for locally advanced head and neck squamous cell carcinoma; trial s…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Head and Neck Squamous Cell Carcinoma

Drugs mentioned

• Anlotinib (anlotinib)
• PD-L1 inhibitor (Programmed death-ligand 1 inhibitor)

Snippet

Sponsor: The First Affiliated Hospital with Nanjing Medical University | Conditions: Head and Neck Squamous Cell Carcinoma, Neoadjuvant Therapy | Phase 2 | Status: NOT_YET_RECRUITING